Novo NordiskNVO
About: With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Employees: 72,000
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
8% more repeat investments, than reductions
Existing positions increased: 690 | Existing positions reduced: 640
0.45% less ownership
Funds ownership: 10.32% [Q2] → 9.86% (-0.45%) [Q3]
4% less funds holding
Funds holding: 1,835 [Q2] → 1,755 (-80) [Q3]
21% less capital invested
Capital invested by funds: $49.9B [Q2] → $39.5B (-$10.3B) [Q3]
32% less call options, than puts
Call options by funds: $791M | Put options by funds: $1.16B
33% less funds holding in top 10
Funds holding in top 10: 89 [Q2] → 60 (-29) [Q3]
35% less first-time investments, than exits
New positions opened: 148 | Existing positions closed: 228
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Cantor Fitzgerald Louise Chen 26% 1-year accuracy 40 / 155 met price target | 88%upside $160 | Overweight Reiterated | 6 Nov 2024 |
BMO Capital Evan David Seigerman 24% 1-year accuracy 4 / 17 met price target | 84%upside $156 | Outperform Maintained | 17 Oct 2024 |
Financial journalist opinion
Based on 106 articles about NVO published over the past 30 days
